Back

AGORA2: Large scale reconstruction of the microbiome highlights wide-spread drug-metabolising capacities.

Heinken, A.; Acharya, G.; Ravcheev, D. A.; Hertel, J.; Nyga, M.; Okpala, O. E.; Hogan, M.; Magnusdottir, S.; Martinelli, F.; Preciat, G.; Edirisinghe, J. N.; Henry, C. S.; Fleming, R. M. T.; Thiele, I.

2020-11-10 systems biology
10.1101/2020.11.09.375451 bioRxiv
Show abstract

The human microbiome influences the efficacy and safety of a wide variety of commonly prescribed drugs, yet comprehensive systems-level approaches to interrogate drug-microbiome interactions are lacking. Here, we present a computational resource of human microbial genome-scale reconstructions, deemed AGORA2, which accounts for 7,206 strains, includes microbial drug degradation and biotransformation, and was extensively curated based on comparative genomics and literature searches. AGORA2 serves as a knowledge base for the human microbiome and as a metabolic modelling resource. We demonstrate the latter by mechanistically modelling microbial drug metabolism capabilities in single strains and pairwise models. Moreover, we predict the individual-specific drug conversion potential in a cohort of 616 colorectal cancer patients and controls. This analysis reveals that some drug activation capabilities are present in only a subset of individuals, moreover, drug conversion potential correlate with clinical parameters. Thus, AGORA2 paves the way towards personalised, predictive analysis of host-drug-microbiome interactions.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.